Form 8-K Oncothyreon Inc. For: Feb 04

�

�

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

�

�

FORM 8-K

�

�

CURRENT REPORT

Pursuant to Section�13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 5, 2015

�

�

ONCOTHYREON INC.

(Exact name of registrant as specified in its charter)

�

�

�

Delaware	�	001-33882	�	26-0868560
(State or other jurisdiction of�incorporation)	�	(Commission File Number)	�	(IRS Employer Identification No.)

2601 Fourth Avenue, Suite 500

Seattle, Washington 98121

(Address of principal executive offices, including zip code)

(206) 801-2100

(Registrant�s telephone number, including area code)

(Former name or former address, if changed since last report)

�

�

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

�

�	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

�

�	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

�

�	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

�

�	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

�

�

�

---

Item�2.02 Results of Operations and Financial Condition

On February�5, 2015, Oncothyreon Inc. (the �Company�) filed with the Securities and Exchange Commission prospectus supplements pursuant to Rule 424(b)(5) of the Securities Act of 1933, as amended (the �Securities Act�), in which the Company disclosed that its cash, cash equivalents and investments were approximately $64 million as of December�31, 2014.

The information furnished with this report shall not be deemed �filed� for purposes of Section�18 of the Securities Exchange Act of 1934, as amended (the �Exchange Act�), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as expressly set forth by specific reference in such a filing.

�

2

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

�

Date: February 5, 2015

�

3

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Sysco Declares Increase to Quarterly Dividend
• Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
• Integrated Financial Holdings, Inc. First Quarter Financial Results